In the past week, MXCT stock has gone up by 13.95%, with a monthly decline of -18.56% and a quarterly plunge of -42.78%. The volatility ratio for the week is 12.74%, and the volatility levels for the last 30 days are 7.75% for MaxCyte Inc The simple moving average for the past 20 days is -3.04% for MXCT’s stock, with a -31.93% simple moving average for the past 200 days.
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MXCT is 97.69M, and at present, short sellers hold a 3.37% of that float. On April 15, 2025, the average trading volume of MXCT was 625.92K shares.
MXCT) stock’s latest price update
The stock price of MaxCyte Inc (NASDAQ: MXCT) has jumped by 2.12 compared to previous close of 2.60. Despite this, the company has seen a gain of 13.95% in its stock price over the last five trading days. globenewswire.com reported 2025-04-10 that ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at -20.73% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.52% of loss for the given period.
Volatility was left at 7.75%, however, over the last 30 days, the volatility rate increased by 12.74%, as shares sank -18.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.23% lower at present.
During the last 5 trading sessions, MXCT rose by +11.59%, which changed the moving average for the period of 200-days by -35.00% in comparison to the 20-day moving average, which settled at $2.74. In addition, MaxCyte Inc saw -36.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Soleymannezhad Ali, who sale 1,211 shares at the price of $3.18 back on Mar 18 ’25. After this action, Soleymannezhad Ali now owns 59,439 shares of MaxCyte Inc, valued at $3,850 using the latest closing price.
Sandoval David I., the GENERAL COUNSEL of MaxCyte Inc, sale 353 shares at $3.18 during a trade that took place back on Mar 18 ’25, which means that Sandoval David I. is holding 64,219 shares at $1,122 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.32 for the present operating margin
- 0.76 for the gross margin
The net margin for MaxCyte Inc stands at -1.06. The total capital return value is set at -0.23. Equity return is now at value -18.73, with -16.17 for asset returns.
Based on MaxCyte Inc (MXCT), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.53.
Currently, EBITDA for the company is -46.41 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 6.95. The receivables turnover for the company is 8.25for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.88.
Conclusion
To sum up, MaxCyte Inc (MXCT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
